

JEAN M. MULCAHY LEVY, M.D.

Assistant Professor of Pediatrics
University of Colorado School of Medicine
Division of Pediatric Hematology, Oncology, and Bone Marrow Transplant
Center for Cancer and Blood Disorders, Children's Hospital Colorado
12800 E. 19th Ave., Peds MS8302, P18-4107
Aurora, CO 80045
Email: Jean.MulcahyLevy@ucdenver.edu
Phone: (303) 724-7893 Fax: (303) 724-4015

EDUCATION and TRAINING

University of Portland, Portland, OR
Bachelor of Science in Biology
August, 1994- May, 1998

Oregon Health & Science University, Portland, OR
Doctor of Medicine
August, 1999- June, 2003

St. Jude Children's Hospital, Memphis, TN
Professional Oncology Education Program
June, 2000-August, 2000

University of Arizona, Tucson, AZ
Residency in Pediatrics
July, 2003-June, 2006

Baylor College of Medicine, Houston, TX
American Society of Tropical Medicine and Hygiene Approved Pre-requisite Course for Certificate of Knowledge in Clinical Tropical Medicine and Traveler's Health
August, 2006

Children's Hospital Colorado, Aurora, CO
Fellowship in Pediatric Hematology, Oncology, and Bone Marrow Transplant
July, 2008-June, 2012

ACADEMIC APPOINTMENTS

Pediatric AIDS Corps Physician
Baylor College of Medicine-Abbot Fund Children's Clinical Center of Excellence, Malawi
July, 2006-August, 2007

Instructor of Pediatrics
Children's Hospital Colorado, Center for Cancer and Blood Disorders
July, 2012-June, 2015

Assistant Professor of Pediatrics
University of Colorado Anschutz Medical Campus
Children's Hospital Colorado, Center for Cancer and Blood Disorders
July, 2015- Current

Assistant Professor of Pharmacology (Secondary Appointment)
University of Colorado Anschutz Medical Campus
May, 2017- Current

OTHER PROFESSIONAL POSITIONS

Scientific Advisory Board Member, Cancer League of Colorado
2017-2019

HONORS and AWARDS

1997 American Heart Association Research Fellowship
1998 *Magna Cum Laude*, University of Portland
2005 Maurice Zee Compassionate Pediatric Resident Aware, University of Arizona

2006 Pediatric Resident Award for Research, University of Arizona
 2006 Pediatric Resident Continuity Clinic Award
 2010 American Society of Clinical Oncology Trainee Travel Award
 2011 AACR Molecular Biology in Clinical Oncology American Association for Cancer Research Workshop Attendee
 2012 Plenary Speaker, International Symposium on Pediatric Neuro-Oncology
 2012 International Symposium on Pediatric Neuro-Oncology, Outstanding Abstract Award
 2009-2018 Grant Recipient, National Institutes of Health Loan Repayment Program
 2018 Finalist, Robert J. Arceci Innovation Award, St. Baldrick's Foundation
 2018 Boettcher Webb-Waring Biomedical Research Award

PROFESSIONAL SOCIETY MEMBERSHIPS

2006-Current American Academy of Pediatrics
 2008-Current American Society of Pediatric Hematology and Oncology
 2008-Current Children's Oncology Group
 2012-Current American Association for Cancer Research
 2012-Current American Society of Clinical Oncology
 2012-Current Society of Neuro-Oncology

MAJOR SERVICE RESPONSIBILITIES

2008-Current Pediatric Advanced Life Support Instructor, Children's Hospital Colorado Life Support Education Program
 2013-Current Center for Cancer and Blood Disorders Faculty Representative, Children's Hospital Colorado Code Committee- Escalation of Care Taskforce
 2015-Current Director of Neuro-Oncology High Dose Therapy/Autologous Transplant Program Children's Hospital Colorado
 2017-2018 Organizing Committee and Co-Chair for Sunrise Sessions, International Symposium on Pediatric Neuro-Oncology
 2017-Current Co-organizer, Childhood Cancer Research Emphasis Area, Center for Cancer and Blood Disorders Research Conference
 2018-Current Center for Cancer and Blood Disorders Faculty Representative, Children's Hospital Colorado Sepsis Clinical Improvement Team
 2018-Current Clinical Lead, Pediatric Neuro-Oncology, Children's Hospital Colorado

LICENSURE and BOARD CERTIFICATION:

Colorado Medical License,
 Original 6/15/07, Most recent renewal: 5/1/17- 4/30/19
 Arizona Medical License,
 Original 5/15/06 (expired)
 Malawi National Antiretroviral Treatment Certification, 2006
 Pediatric Advance Life Support Instructor Certification, 2008-present
 American Board of Pediatrics Certified, October 2007
 American Board of Pediatrics Sub-Board Certified, Pediatric Hematology/Oncology, April 2013

REVIEW AND REFEREE WORK

2013- Current Peer Reviewer, St. Baldrick's Foundation Research Grant Review Committee
 2014 Ad Hoc Peer Reviewer, *International Journal of Molecular Sciences*
 2014- Current Ad Hoc Peer Reviewer, *Pediatric Blood and Cancer*
 2014- Current Ad Hoc Peer Reviewer, *Autophagy*
 2015 Ad Hoc Peer Reviewer, *Children*
 2015- Current Ad Hoc Peer Reviewer, *Oncotarget*
 2015- Current Ad Hoc Peer Reviewer, *Scientific Reports*
 2016 Ad Hoc Peer Reviewer, *Oncology Letters*
 2017 Ad Hoc Peer Reviewer, *Bone Marrow Transplantation*
 2017 Ad Hoc Peer Reviewer, *Nature Medicine*
 2017-Current Ad Hoc Peer Reviewer, *PLOS ONE*
 2017- Current Peer Reviewer, Pediatric Cancer Research Foundation

2017 Ad Hoc Peer Reviewer, JCO Precision Oncology
2017-Current Peer Reviewer, Cancer League of Colorado

INVITED LECTURES AND PRESENTATIONS

- 2013 Department of Pediatrics Basic and Translational Pediatric Research Seminar Series
Autophagy Inhibition and Brain Tumors: The Potential for Use in Pediatrics
- 2014 Autophagy: From Basics to Clinical Application Symposium
The Interleukin Foundation and the Division of Infectious Diseases, University of Colorado
Autophagy as a Target for Cancer Therapy
- 2015 University of Colorado Developmental Therapeutics Retreat
Autophagy Inhibition and Re-sensitization of Mutant BRAF Tumor
- 2016 Centro de Investigación Biomédica de Oriente (CIBIOR) Research Series
Targeting Autophagy to Improve Pediatric Brain Tumor Therapy
- University of Michigan Pediatric Neuro-Oncology Precision Medicine Conference
Overcoming Resistance Mechanisms to Targeted Therapies in Low-Grade Glioma
- Children's Oncology Group Fall Meeting
Overcoming Resistance Mechanisms to Targeted Therapies in Low-Grade Glioma
- Huntsman Cancer Institute of the University of Utah
Autophagy Inhibition to Improve Pediatric Brain Tumor Therapy
- University of Colorado Cancer Center Symposium
Targeting Autophagy to Improve Brain Tumor Therapy
- 2017 University of Colorado Department of Pharmacology
Candidate for Secondary Faculty Appointment
Autophagy Inhibition to Improve Survival in Childhood Brain Tumors
- University of Colorado Department of Pediatrics, Center for Cancer and Blood Disorders
Childhood Cancer Research Emphasis Area
Autophagy Inhibition to Improve Survival in Childhood Brain Tumors
- Children's Hospital of Philadelphia
Division of Oncology Center for Childhood Cancer Research
Autophagy Inhibition to Improve Survival in Childhood Brain Tumors
- 2018 The Banbury Center, Cold Springs Harbor Laboratory
Autophagy and Cancer Meeting
Pre-clinical Development of Autophagy Inhibition for Brain Tumors
- Hospital for Sick Children, Division of Hematology Oncology
Toronto, Ontario
Pre-clinical and Clinical Development of Autophagy Inhibition for Brain Tumors

TEACHING RECORD

Small Group Facilitator (IDPT5003), Problem Based Learning, Blood and Lymph Section
University of Colorado School of Medicine, 2009-present

Attending Physician, Pediatric Oncology and Bone Marrow Transplant Inpatient Services, Supervision and bedside teaching of fellows, residents, and nurse practitioner students.
Children's Hospital Colorado, 2012 – present

Attending Physician, Pediatric Neuro-Oncology Outpatient Service, Supervision and teaching of fellows, residents and nurse practitioner students.

Children's Hospital Colorado, 2012 – present

Foundations of Doctoring (IDPT 7655),

Preceptor for Michelle Kuei, MD

University of Colorado School of Medicine, 2013-2016

Preceptor for Simon Feseha, MD Candidate

University of Colorado School of Medicine, 2017-current

Escalation Curriculum Facilitator, Rising PL2 and Rising PL3 Pediatric Residents

Children's Hospital Colorado, 2017

Molecules to Medicine Lecturer, Phase I Essential Core Curriculum for MS1 Students

University of Colorado School of Medicine, 2017

Facilitator, Critical Care and Procedures Bootcamp

Children's Hospital Colorado, 2015-2018

MENTORING POSITIONS

Research Rotation Mentor, Sarah Williams, Graduate Student

2010

Research Rotation Mentor, Jenna Hirsch, Summer Research Intern

2011

Summer Research Intern. Sydney Grob, undergraduate, Duke University

Publication: **Grob, ST**; Mulcahy Levy, JM. *Improving diagnostic and therapeutic outcomes in pediatric brain tumors.* Mol Diagn Ther, 2017 Sep 12. DOI 10.1007/s40291-017-0299-3

Summer Research Intern. Caroline Soane, undergraduate, Stanford University

Poster Presentation, International Symposium on Pediatric Neuro-Oncology, 2018. Morin, A; **Soane, C**; Pierce, A; Alimova, I; Desmarais, M; Zahedi, S; Vibhakar, R; Griesinger, A; Green, A; Hoffman, L; Mulcahy Levy, JM. "Validation of Proteasome Inhibition as a Therapeutic Target in Atypical Teratoid/Rhabdoid Tumors."

Medical Student Class of 2021 Research Track. Eliza Baird-Daniel

Career Mentor,

2011- present Lindsey Hoffman, Assistant Professor, University of Colorado

Successful completion of Neuro-oncology Fellowship, Cincinnati Children's Hospital

2015- present Amanda Winters, Fellow, University of Colorado

Promoted to Instructor Fellow, July 2017

Awarded Cancer League of Colorado Research Award, 2017

Awarded St. Baldrick's Foundation Fellowship Award, 2017-2019

2016- present Jenna Sopfe, Fellow, University of Colorado

Awarded Thrasher Foundation Early Career Research Award, 2017

Awarded Cancer League of Colorado Fellowship Award, 2017

Promoted to Assistant Professor, 2018

2016- present Nathan Dahl, Fellow, University of Colorado

First author publication in Journal of Neuropathology & Experimental Neurology, 2017

Dahl, NA; Luebbert, T; Loi, M; Neuberger, I; Handler, MH; Kleinschmidt-DeMasters, BK; Mulcahy Levy, JM. *Chordoma occurs in young children with tuberous sclerosis*. JNEN, doi: 10.1093/jnen/nlx032

Awarded Cancer League of Colorado Research Award, 2018

2016- present Susan Kuldaneck, Fellow, University of Colorado

2016-present Christina G. Towers, Post-doctoral Researcher, University of Colorado
Co-mentor to post-doctoral researcher in the lab of Dr. Andrew Thorburn, providing clinical and translational research experience to complement her basic science research. Publications: Mulcahy Levy, JM; **Towers, CG**; Thorburn, A. *Targeting autophagy in cancer*. Nat Rev Cancer, 2017 Sep;17(9):528-542. doi: 10.1038/nrc.2017.53

2017- present Kelly Faulk, Fellow, University of Colorado
Awarded Baldrick's Foundation Fellowship, 2018

2017-present Jessica Lake, Fellow, University of Colorado
Successful application to multiple American Association for Cancer Research fellowship grants.

Faculty Expert: NIH K Award Grant Planning (Office of Research Development and Education Seminar) 2016, 2019

Fellow and Early Career Grant Writing Mentorship

2016- present Amanda Winters

2017- present Jenna Sopfe

2017- present Kelly Faulk

2017- present Jessica Lake

2017-present Nathan Dahl

Children's Hospital Colorado Child Health Research Internship Mentor,

2016 Brennan Requist, Summer Research Intern. Applicant for PhD programs, 2018

2017 Caroline Soane, Summer Research Intern. Applicant for MD programs, 2018

2018 Sharon Reddy, Summer Research Intern.

GRANT SUPPORT

Current Support

NIH-National Cancer Institute K08 Career Development Award	
Role	Primary Investigator
Grant #	1K08CA193982-01A1
Dates	9/18/15-09/17/20
% effort	75%
Direct costs	\$761,080
Goal	To examine the interaction of autophagy with the BRAF ^{V600E} mutation in brain tumors.

Team Connor Childhood Cancer Foundation	
Role	Primary Investigator
Grant #	N/A
Dates	1/1/18 – 12/31/18
% effort	2%
Direct costs	\$62,619
Goal	Validation of proteasome inhibition as a therapeutic target in atypical teratoid/rhabdoid tumors.

Department of Defense Peer Reviewed Cancer Research Program Expansion Award	
Role	Primary Investigator
Grant #	CA170414
Dates	7/1/18-6/30/20
% effort	7.2%
Direct costs	\$344,972
Goal	Optimization of Autophagy Inhibition as a Clinical Target for Brain Tumors

Boettcher Webb-Waring Biomedical Research Award	
Role	Primary Investigator
Grant #	n/a
Dates	7/1/18-6/30/21
% effort	1%
Direct costs	\$235,000
Goal	Pre-Clinical Development of Autophagy Inhibition for an Expanded Population of Central Nervous System Tumors

NIH Loan Repayment Program	
Role	Primary Investigator
Grant #	N/A
Dates	2009-2018
Direct costs	Funds provided to repay student loan debt

Completed Support

St. Baldrick's Foundation Career Development Award Competitive Extension	
Role	Primary Investigator
Grant #	N/A
Dates	7/1/15-6/30/17
% effort	5%
Direct costs	\$230,000
Goal	To determine clinical potential for autophagy manipulation in pediatric brain tumors.

Alex's Lemonade Stand Foundation Young Investigator Award	
Role	Primary Investigator
Grant #	N/A
Dates	7/1/14-6/30/16
% effort	5
Direct costs	\$100,000
Goal	To examine the interaction of autophagy with the BRAF ^{V600E} mutation and the mTOR pathway in brain tumors.

Department of Defense Career Development Award	
Role	Primary Investigator
Grant #	CA130562
Dates	7/1/14-6/30/16 (Relinquished 9/17/15 due to overlap)
% effort	40

Direct costs	\$240,000
Goal	To examine the interaction of autophagy with the BRAF ^{V600E} mutation in brain tumors.

American Cancer Society Mentored Research Scholar Grant	
Role	Primary Investigator
Grant #	MMSG TBG- 125962
Dates	7/1/14-6/30/19 (Relinquished due to overlap)
% effort	40
Direct costs	\$675,000
Goal	To examine the interaction of autophagy with the BRAF ^{V600E} mutation in brain tumors.

St. Baldrick's Foundation Career Development Award	
Role	Primary Investigator
Grant #	N/A
Dates	7/1/12-6/30/15
% effort	25%
Direct costs	\$330,000
Goal	To determine clinical potential for autophagy manipulation in pediatric brain tumors.

NIH-UCSOM K12 CHR Career Development Award	
Role	Primary Investigator
Grant #	K12 68372
Dates	7/1/12-6/30/14
% effort	50%
Direct costs	\$\$285,683
Goal	To develop new targets for autophagy inhibition and determine which pediatric neural tumors are dependent on autophagy for growth.

Hyundai Hope on Wheels	
Role	Primary Investigator
Grant #	N/A
Dates	9/1/11- 8/30/13
% effort	5%
Direct costs	\$75,000
Goal	Evaluation of autophagy inhibition in primary patient derived short-term cultures and in vivo modeling of tumor response.

St. Baldrick's Foundation Fellowship Award	
Role	Primary Investigator
Grant #	N/A
Dates	7/1/09-6/30/12
% effort	100%
Direct costs	\$240,212
Goal	Determine if autophagy induction and inhibition in pediatric glioblastoma, medulloblastoma, and AT/RT cell lines determines chemosensitivity.

Cancer League of Colorado	
----------------------------------	--

Role	Co-Primary Investigator
Grant #	N/A
Dates	7/1/11-6/30/12
% effort	1%
Direct costs	\$60,000
Goal	To apply functional genetic screening to define the contextual role of autophagy in pediatric neural tumors.

BIBLIOGRAPHY

Peer Reviewed

1. KP Battaile, RL Bateman, D Mortimer, **J Mulcahy**, RK Rathbun, G Bagby, WH Fleming, and M Grompe. *In Vivo Selection of Wild-Type Hematopoietic Stem Cells in a Murine Model of Fanconi Anemia* Blood 1999 94(6): 2151-2158.
2. WH Fleming, **JM Mulcahy**, JP McKearn, PR Streeter. *Progenipoietin-1: A Multifunctional Agonist of the Granulocyte Colony-Stimulating Factor Receptor and Fetal Liver Tyrosine Kinase-3 is a Potent Mobilizer of Hematopoietic Stem Cells*. Experimental Hematology 2001, 29(8): 943-951
3. MJ Montfort, C Olivares, **JM Mulcahy**, WH Fleming. *Adult Blood Vessels Restore Host Hematopoiesis Following Lethal Irradiation*. Experimental Hematology 2002 30(8) 950-956.
4. Keating A.K., Kim, G.K., Jones, A., Donson A., Ware, K., **Mulcahy, J.**, Salzberg, D.B., Foreman N., Liang, X., Thorburn, A., Graham D.K. *Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity*. Molecular Cancer Therapeutics, 2010, 9(5): 1298-307.
5. **Levy, JM.**, Thorburn, A. *Targeting Autophagy during Cancer therapy to Improve Clinical Outcomes*. Pharmacology and Therapeutics, 2011, 131(1): 130-41.
6. **Levy, JM.**, Thorburn, A. *Modulation of pediatric brain tumor autophagy and chemosensitivity*. J Neurooncol, 2012, 106(2): 281-90.
7. **Mulcahy Levy, JM.**, Tello, T., Giller, R., Wilkening, G., Quinones, R., Keating, A., Liu, AK. *Late Effects of Total Body Irradiation and Hematopoietic Stem Cell Transplant in Children Under Three Years of Age*. Pediatr Blood Cancer. 2012, doi: 10.1002/pbc.24252.
8. **Mulcahy Levy JM**, Hunger SP. *Brain size and neuropsychological functioning in long-term survivors of pediatric acute lymphoblastic leukemia*. Transl Pediatr 2013 Aug 15. doi: 10.3978/j.issn.2224-4336.2013.08.02
9. Kulbe JR*, **Mulcahy Levy JM***, Coultrap SJ, Thorburn A, Bayer KU. *Excitotoxic glutamate insults block autophagic flux in hippocampal neurons*. Brain Research 2014, 1542 (13): 12-9. *Authors with equal contribution.
10. Donson AM, Kleinschmidt-DeMasters BK, Aisner DL, Bemis LT, Birks, DK, **Mulcahy Levy JM**, Smith AA, Handler MH, Foreman NK, Rush SZ. *Pediatric brainstem gangliogliomas show BRAF^{V600E} in a high percentage of cases*. Brain Pathology 2014, 24 (2); 173-183.
11. Maycotte P, Gearheart, CM, Barnard, R, Aryal, S. **Mulcahy Levy, JM**, Fosmire, SP, Hansen, RJ, Morgan, MJ, Porter, CC, Gustafson, DL, Thorburn, A. *STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious*. Cancer Res 2014 May 1;74(9):2579-90. doi: 10.1158/0008-5472.CAN-13-3470
12. **Mulcahy Levy, JM**, Thompson, JC, Griesinger, AM, Amani, V, Donson, AM, Birks, DK, Morgan, MJ, Mirsky, DM, Handler, MH, Foreman, NK, Thorburn, A. *Autophagy inhibition improves chemosensitivity in BRAF^{V600E} brain tumors*. Cancer Discov. 2014 Jul;4(7):773-80. doi: 10.1158/2159-8290.CD-14-0049
13. **Mulcahy Levy, JM**, Foreman, NK, Thorburn, A. *Using BRAF^{V600E} as a Marker of Autophagy Dependence in Pediatric Brain Tumors*. Autophagy 2014; 10(11): 2077-8. doi: 10.4161/auto.36138
14. Dudley, RWR, Torok, MR, Gallegos, D, **Mulcahy Levy, JM**, Hoffman L, Liu, AK, Handler, MH, Hankinson, TC. *Pediatric Low Grade Ganglioglioma: Epidemiology, Treatments, and Outcome Analysis on 331 Children From the SEER Database*. Neurosurgery. 2015; 76(3): 313-320.
15. Koo, G.-B.*, Morgan, M.J.*, Lee, D.-G., Kim, W.-J., Yoon, J.-H., Koo, J.S., Kim, S.I., Kim, S.J., Son, M.K., Hong, S.S., **Mulcahy Levy, JM.**, Pollyea, D.A., Jordan, C.T., Yan, P., Frankhouser, D., Nicolet, D., Maharry, K., Marcucci, G., Choi, K.S., Cho, H., Thorburn, A., and Y.-S.Kim. *Methylation-Dependent Loss of RIP3 Expression in Cancer Represses Programmed Necrosis in*

- Response to Chemotherapeutics*. *First Authors/ Equal contribution. *Cell Research*. 2015; 25: 707-725, doi: 10.1038/cr.2015.56.
16. Griesinger, AM., Josephson, RJ., Donson, AM., **Mulcahy Levy, JM**, Amani, V., Birks, DK., Hoffman, LM., Handler, MH., Vibhakar, R., Foreman, NK. *Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in Group A ependymoma*. *Cancer Immunol Res*. 2015, May 3(5): 526-535. doi: 10.1158/2326-6066.CIR-15-0061.
 17. Klionsky DJ, Abdelmohsen K, ...**Mulcahy Levy, JM**, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*. 2016;12(1):1-222.
 18. Goodall, ML; Fitzwalter, B; Zahedi, S; Wu, M; Rodriguez, D; **Mulcahy Levy, JM**; Green, DR; Morgan, M; Cramer, S; Thorburn, A. *The Autophagy Machinery Controls Cell Death Switching between Apoptosis and Necrosis*. *Developmental Cell*, 2016 May 23; 37(4):337-49. doi: 10.1016/j.devcel.2016.04.018.
 19. Prince, E., Balakrishnan, I., Shah, M., **Mulcahy Levy, JM.**, Griesinger, A., Alimova, I., Harris, P., Birks, D., Donson, A., Davidson, N., Remke, M., Taylor, M., Handler, M., Foreman, N., Venkataraman, S., & Vibhakar, R. *Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma*. *Oncotarget*, 2016 Aug 16;7(33):53881-53894. 19. doi: 10.18632/oncotarget.10692.
 20. Amani, V., Alimova, I., Balakrishnan, I., Birks, D., Donson, AM., Harris, P., **Mulcahy Levy, JM.**, Handler, M., Foreman, NK., Venkataraman, S., Vibhakar, R. Polo-like kinase 1 as a potential therapeutic target in diffuse pontine glioma. *BMC Cancer*. 2016 Aug 18;16:647. doi: 10.1186/s12885-016-2690-6.
 21. **Mulcahy Levy, JM**; Zahedi, S; Griesinger, AM; Davies, KD; Aisner, DL; DeMasters, BK; Fitzwalter, BE; Goodall, ML; Amani, V; Donson, AM; Birks, DK; Mirsky, DM; Hankinson, TC; Handler, MH; Foreman, NK; Thorburn, A. *Autophagy Inhibition Overcomes Clinically Acquired Resistance to BRAF Inhibition in Brain Tumors*. *eLife*. 2017 Jan 17;6: pii: e19671. doi: 10.7554/eLife.19671
 22. Griesinger, AM; Witt, DA; Grob, ST; Georgio Westover, SR; Donson, AM; Sanford, B; **Mulcahy Levy, JM**; Wong, R; Moreira, DC; DeSisto, JA; Balakrishnan, I; Hoffman, LM; Handler, MH; Jones, KL; Vibhakar, R; Venkataraman, S; Foreman, NK. *NF- κ B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma*. *Neuro-Oncol*. 2017 May 16. doi: 10.1093/neuonc/nox061.
 23. Green, AL; **Mulcahy Levy, JM**; Vibhakar, R; Hemenway, M; Madden, J; Foreman NK; Doris, K. *Tumor Treating Fields in Pediatric High-Grade Glioma*. *Childs Nerv Syst*, 2017 May 3. doi: 10.1007/s00381-017-3431-0.
 24. Dahl, NA; Luebbert, T; Loi, M; Neuberger, I; Handler, MH; Kleinschmidt-DeMasters, BK; **Mulcahy Levy, JM**. *Chordoma occurs in young children with tuberous sclerosis*. *JNEN*, 2017 Jun 1; 76(6): 418-423doi: 10.1093/jnen/nlx032.
 25. Lassaletta, A; Mistry, M; Ramaswamy, V; Honnorat, M; Zapotocky, M; Krishnatry, R; Stucklin, AG; Zhukova, N; Arnaldo, A; Ryall, S; Ling, C; McKeown, T; Cruz, O; Gomez-Pallete, C; Ho, C; Packer, R; Tatevossian, R; Ellison, D; Harreld, J; Dalton, J; **Mulcahy Levy, J**; Foreman, N; Karajanis, M; Rao, AN; Kieran, M; Ligon, K; Garre, ML; Nozza, P; Mascelli, S; Raso, A; Mueller, S; Nicolaides, T; Jouvett, A; Perbert, R; Vasiljevic, A; Frappaz, D; Leary, S; Crane, C; Chan, A; Ng, HK; Zhi-feng, S; Finch, E; Eisenstat, D; Wilson, B; Carret, AS; Hauser, P; Sumerauer, D; Larouche, V; Fleming, A; Zelcer, S; Jabado, N; Bartels, U; Huang, A; Bouffet, E; Hawkins, C; Tabori, U. *Therapeutic and prognostic implications of BRAF-V600E in pediatric low grade gliomas*. *J Clin Oncol*, 2017 Sep 1;35(25):2934-2941. doi: 10.1200/JCO.2016.71.8726
 26. **Mulcahy Levy, JM**; Towers, CG; Thorburn, A. *Targeting autophagy in cancer*. *Nat Rev Cancer*, 2017 Sep;17(9):528-542. doi: 10.1038/nrc.2017.53
 27. Marini B, Benitez L, Zureick A, Salloum R, Gauthier A, Brown J, Wu Y, Robinson D, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey J, Camelo-Piragua S, Venneti S; Mc Keever P, McFadden K, Lieberman A, Brown N, Shao L, Leonard M; Junck L, McKean E, Maher C, Garton H, Muraszko K, Hervey-Jumper S, **Mulcahy-Levy J**, Green A, Hoffman L, Dorris K, Vitanza N, Wang J, Schwartz J, Lulla R, Pillay Smiley N, Bornhorst M, Haas-Kogan D, Robertson P, Chinnaiyan A, Mody R and Koschmann C. *Blood brain barrier-adapted precision medicine therapy for pediatric brain tumors*. *Transl Res*, 2017 Oct;188:27.e1-27.e14. doi: 10.1016/j.trsl.2017.08.001
 28. Grob, ST; **Mulcahy Levy, JM**. *Improving diagnostic and therapeutic outcomes in pediatric brain tumors*. *Mol Diagn Ther*, 2017 Sep 12.DOI 10.1007/s40291-017-0299-3

29. Yang, MJ*; Whelan, R*; Madden, J; **Mulcahy Levy, JM**; DeMasters, BK; Hankinson, TC; Foreman, NK; Handler, MH. Intracranial Ewing sarcoma: four pediatric examples. Childs Nerv Syst, 2017 Dec 28. doi: 10.1007/s00381-017-3684-7.
30. Michniacki, T; **Mulcahy Levy, JM**; Quinones, RR; Giller, RH. Successful correction of familial hemophagocytic lymphohistiocytosis using prenatal genetic testing and preemptive hematopoietic stem cell transplantation. Bone Marrow Transplant, 2018 Feb;53(2):223-224. doi: 10.1038/bmt.2017.219.
31. Flannery, PC*; DeSisto, JA*; Amani, V; Venkataraman, S; Lemma, RT; Prince, EW; Donson, A; Moroze, EE; Hoffman, L; **Mulcahy Levy, JM**; Foreman, N; Vibhakar, R; Green AL. Preclinical Analysis of MTOR Complex ½ Inhibition in Diffuse Intrinsic Pontine Glioma. Oncol Rep, 2018 Feb;39(2):455-464. doi: 10.3892/or.2017.6122.
32. DeMasters, BK; **Mulcahy Levy, JM**. H3 K27M-mutant Gliomas in Adults vs. Children share similar histological features and adverse prognosis. Clinical Neuropathology, 2018 Mar/Apr; 37 (2):53-63. doi: 10.5414/NP301085.
33. Nellan, A; Rota, C; Majzner, R; Lester-McCully, CM; Griesinger, AM; **Mulcahy Levy, JM**; Foreman, NK; Warren, KE; Lee, DQ. Durable regression of medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T-cells. J Immunother Cancer, 2018 Apr 30;6(1):30. doi: 10.1186/s40425-018-0340-z.
34. Dudley, RW; Torok, M; Randall, S; Beland, B; Handler, M; **Mulcahy Levy, JM**; Liu, A; Hankinson, T. Pediatric versus adult meningioma: comparison of epidemiology, treatments, and outcomes using the Surveillance, Epidemiology, and End Results database. J of Neuro-Oncol. 2018 May;137(3):621-629. doi: 10.1007/s11060-018-2756-1.
35. Witt, DA; Donson, AM; Amani, V; Moreira, DC; Sanford, B; Hoffman, LM; Handler, MH; **Mulcahy Levy, JM**; Jones, KL; Nellan, A; Foreman, NK; Griesinger, AM. Specific expression of PD-L1 in RELA-Fusion supratentorial ependymoma: Implications for PD-1 targeted therapy, Pediatr Blood Cancer, 2018 May;65(5): e26960. doi: 10.1002/pbc.26960.
36. Donson, AM; Amani, V; Warner, EA; Griesinger, AM; Witt, DA; **Mulcahy Levy, JM**; Hoffman, LM; Hankinson, TC; Handler, MH; Vibhakar, R; Dorris, K; Foreman, NK. Identification of FDA-approved oncology drugs with selective potency in high-risk childhood ependymoma. Mol Cancer Ther, 2018 June 20, pii: molcanther.1185.2017. doi: 10.1158/1535-7163.MCT-17-1185.
37. **Mulcahy Levy, JM**; McMahon, M. Linking brain tumors and epileptic seizures. Nat Med, 2018 Nov;24(11): 1638-1639. doi: 10.1038/s41591-018-0249-6

Book Chapters

1. Graham, DK; Craddock, JA; Quinones, RR; Keating; AK; Maloney, K; **Mulcahy Levy, JM**, Giller, RH, Greffe, BS. "Neoplastic Disease." *Current Diagnosis and Treatment Pediatrics*.

Abstracts (Competitive)

1. **Mulcahy J**, Minnette M, Rice MJ. Children's Knowledge of Kawasaki Disease. Pediatric Research 1998, 43 (4), Suppl.: 327A
2. **Mulcahy J**, Minnette M, Rice MJ. Parental Knowledge of Kawasaki Disease. Pediatric Research 1998, 43 (4), Suppl.: 327A
3. Fleming WH, **Mulcahy JM**, McKearn JP, Streeter PR. Progenipoyetin Mobilizes Substantial Numbers of Transplantable Hematopoietic Stem Cells. Blood 1998, 92 (10), Suppl.: 56A.
4. Archer DR, Hester LE, **Mulcahy JM**, Yeager AM, Fleming. WH The Transplantation Potential of Adult and Fetal Murine Stem Cells is Determined By the Recipient Hematopoietic Microenvironment. Blood 1998, 92 (10), Suppl.: 56A.
5. Montfort MJ, **Mulcahy JM**, Fleming WH. Hematopoietic Potential of Adult Blood Vessels. Blood 1999, 94 (10), Suppl.: 34A.
6. Fleming WH, **Mulcahy JM**, McKearn JP, Streeter PR. Multifunctional Agonist of the G-CSF and FLT3 Receptors Has a Greater Stem Cell Mobilizing Activity than Co-administration of G-CSF and FLT3L. Blood 1999, 94 (10), Suppl.: 49A.
7. **Mulcahy JM**, Bagatell R, Whitesell L. Neuroblastoma Cell Line Sensitivity to a Novel Heat Shock Protein 90 Inhibitor. Poster presentation. American Academy of Pediatrics National Conference and Exposition, 2006.
8. **Mulcahy Levy JM**, Thorburn A. The Role of Autophagy in Pediatric Brain Tumors. Poster presentation. Keystone Symposia on Molecular and Cellular Biology, March, 2010.

9. **Mulcahy Levy JM**, Thorburn A. *Modulation of Pediatric Brain Tumor Autophagy and Chemoresensitivity*. Poster presentation. Pediatric Neuro-Oncology Basic and Translational Research Conference, May, 2011. Neuro-Oncology 2011, 13 (Suppl 1).
10. **Mulcahy Levy, JM.**, Tello, T., Lu, X., Gao, D., Wilkening, G., Donson, A., Foreman, N., Liu, AK. *Genetic Predictors of Neurocognitive Outcomes in Survivors of Pediatric Brain Tumors*. Platform Presentation. International Symposium on Pediatric Neuro-Oncology, June, 2012. Neuro-Oncology 2012, 14 (Suppl 1).
11. Amani VM, Griesinger AM, Donson AM, Bemis LT, Birks DK, Schittone SA, Morgan M, Thorburn A, Foreman NK, **Mulcahy Levy JM**. *BRAF V600E in Pediatric Brain Tumors: Specificity of Vemurafenib Treatment and Autophagy-Related Cell Death*. Poster presentation. Society of Neuro-oncology Annual Meeting, November 2012. Neuro-Oncology 2012, 14 (Suppl 6).
12. Griesinger A, Donson A, Hoffman L, Amani V, Birks D, Handler M, **Mulcahy Levy J**, Foreman N. *Rationale for Trastuzumab Therapeutic Antibody Treatment in Ependymoma*. Pediatric Neuro-Oncology Basic and Translational Research Conference. May 2013. Neuro-Oncology 2013 15 (Suppl 1).
13. Thompson, J. Griesinger A, Foreman N, Rush S, **Mulcahy Levy J**. *Correlation of CSF and Serum Biomarkers of Oxidation in Pediatric Brain Tumor Patients*. Pediatric Neuro-Oncology Basic and Translational Research Conference. May 2013. Neuro-Oncology 2013, 15 (Suppl 1).
14. **Mulcahy Levy, JM.**, Thompson, JC, Griesinger, AM, Amani, V, Donson, AM, Birks, DK, Morgan, MJ, Handler, MH, Foreman, NK, Thorburn, A. *BRAF^{V600E} Pediatric Brain Tumors are Sensitive to Autophagy Inhibition*. International Symposium on Pediatric Neuro-Oncology, June, 2014. Neuro-Oncology 2014, 16 (Suppl 1).
15. Donson, A., Kleinschmidt-DeMasters, BK., Aisner, D., Bemis, L., Birks, D., **Mulcahy Levy, J.**, Smith, A., Handler, M. Rush, S., Foreman, N. *Pediatric Brainstem Gangliogliomas show BRAFV600E Mutation in a High Percentage of Cases*. International Symposium on Pediatric Neuro-Oncology, June, 2014. Neuro-Oncology 2014, 16 (Suppl 1).
16. Griesinger A, Josephson R, Donson A, **Mulcahy Levy J**, Amani V, Birks D, Hoffman L, Vibhakar R, Handler M, Foreman N. *Activation of the IL6/STAT3 Pathway in Childhood Ependymoma is Associated with a Pro-inflammatory Tumor Microenvironments and a Poor Prognosis*. Pediatric Neuro-Oncology Basic and Translational Research Conference. May 2015. Neuro-Oncology 2015 17 (Suppl 3).
17. Griesinger A, Josephson R, Donson A, **Mulcahy Levy J**, Amani V, Birks D, Hoffman L, Vibhakar R, Handler M, Foreman N. *Activation of the IL6/STAT3 Pathway in Childhood Ependymoma is Associated with a Pro-inflammatory Tumor Microenvironments and a Poor Prognosis*. Pediatric Neuro-Oncology Basic and Translational Research Conference. May 2015. Neuro-Oncology 2015 17 (Suppl 3).
18. Donson A, Griesinger A, Birks D, Amani V, **Mulcahy Levy J**, Handler M, Dorris K, Foreman N. *Anti-tumor Effect of Trastuzumab, GM-CSF and IL-2 Combinatorial Therapy in Pediatric Ependymoma*. Pediatric Neuro-Oncology Basic and Translational Research Conference. May 2015. Neuro-Oncology 2015 17 (Suppl 3).
19. Griesinger A, Donson A, **Mulcahy Levy J**, Amani V, Birks D, Vibhakar R, Handler M, Foreman N. *Inflammation Driver, NF-kB, is Associated with Poor Outcome Group A Ependymoma and Regulates a Key Immune Suppressive Signaling Pathway Involved in the Tumor Microenvironment*. Pediatric Neuro-Oncology Basic and Translational Research Conference. May 2015. Neuro-Oncology 2015 17 (Suppl 3).
20. Zahedi S, Griesinger A, Handler M, Foreman N, Thorburn A, **Mulcahy Levy J**. *Autophagy Inhibition Reverses Resistance to Targeted BRAF Therapy in Pediatric CNS Tumors*. Pediatric Neuro-Oncology Basic and Translational Research Conference. May 2015. Neuro-Oncology 2015 17 (Suppl 3).
21. Griesinger, A; Wong, R; Grob, Sydney; Venkataraman, S; Balakrishnan, I; Donson, A; **Mulcahy Levy, J**; Vibhakar, R; Handler, M; Foreman, N. *Epigenetic Silencing of LCOD1 Leads to Chronic IL-6 Secretion Through Upregulation of NF-kB Pathway in Group A Ependymoma: Potential for Tailored Therapies*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2018, 18 (Suppl 3).
22. Griesinger, A; Josephson, R; Donson, A; **Mulcahy Levy, J**; Amani, V; Dirks, D; Hoffman, L; Vibhakar, R; Handler, M; Foreman, N. *Activation of the IL6/STAT3 Pathway in Childhood Ependymoma is Associated with a Pro-inflammatory Tumor Microenvironment and a Poor*

- Prognosis*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2018, 18 (Suppl 3).
23. Donson, A; Griesinger, A; **Mulcahy Levy, J**; Amani, V; Handler, M; Hankinson, T; Dorris, K; Foreman, N. *GM-CSF is Critical for Trastuzumab Efficacy in Pediatric Ependymoma*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2016, 18 (Suppl 3).
 24. Venkataraman, S; Davidson, N; Samson, J; Balakrishnan, I; Birks, D; Alimova, I; Amani, V; Prince, E; Donson, A; **Mulcahy Levy, J**; Green, A; Gupta, N; Hashizume, R; Huellman, E; Monje, M; Foreman, N; Vibhakar, R. *Synthetic Lethal Epigenetic Interactions in K27M Mutated DIPG*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2016, 18 (Suppl 3).
 25. Green, A; Foreman, N; **Mulcahy Levy, J**; Madden, J; Hemenway, M; Vibhakar, R; Dorris, K. *Case Series of Three Pediatric Brain Tumor Patients Treated with Tumor Treating Fields*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2016, 18 (Suppl 3).
 26. Lassaletta, A; Mistry, M; Arnaldo, A; Ryall, S; Guerreiro-Stucklin, A; Krishnatry, R; Linc, C; Honnorat, M; Zhukova, N; Zapotocky, M; McKeown, T; Ramaswamy, V; Bartels, U; Huang, A; Jabado, N; Cruz, O; de Torres, C; Cherry, H; Packer, R; Tatevossian, R; Ellison, D; Harreld, J; Dalton, J; **Mulcahy Levy, J**; Foreman, N; Karajannis, M; Mueller, S; Nicolaidis, T; Eisenstat, D; Carret, A; Kieran, M; Ligon, K; Jouvett, A; Perbert, R; Vasiljevic, A; Frappaz, D; Joly, M; Chambeless, L; Thompson, R; Rao, A; Chan, A; Ng, Hk; Garre, M; Nozza, P; Massimino, M; Leary, S; Crane, C; Bouffet, E; Hawkins, C; Tabori, U. *Inferior Outcome and Poor Response to Conventional Therapies in Pediatric Low-Grade Gliomas Harboring the BRAF V600E Mutation*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2016, 18 (Suppl 3).
 27. Dorris, K; Hemenway, M; Madden, J; **Mulcahy Levy, J**; Ambruso, D; Vibhakar, R; Foreman, N. *Use of Cannabinoids in the Pediatric Central Nervous System Tumor Population*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2018, 18 (Suppl 3).
 28. Dorris, K; Hemenway, M; Green, A; Madden, J; **Mulcahy Levy, J**; Vibhakar, R; Foreman, N; McCourt, E. *Improvement in Visual Acuity of Pediatric Patients with Brain Tumors Treated with Bevacizumab*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2016, 18 (Suppl 3).
 29. **Mulcahy Levy, JM**; Zahedi, S; Griesinger, AM; Davies, KD; Aisner, DL; DeMasters, BK; Fitzwalter, BE; Goodall, ML; Amani, V; Donson, AM; Birks, DK; Mirsky, DM; Hankinson, TC; Handler, MH; Foreman, NK; Thorburn, A. *Autophagy Inhibition Overcomes Resistance to BRAF Inhibition in Brain Tumors*. International Symposium on Pediatric Neuro-Oncology, June, 2016. Neuro-Oncology 2016, 18 (Suppl 3).
 30. Alimova, I; Venkataraman, S; Balakrishnan, I; Pierce, AM; **Mulcahy Levy, JM**; Foreman, NK; Vibhakar, R. *An epigenome directed functional genomic screen identifies SIRT2 as a synthetic lethal target in SMARCB1 deficient ATRT*. Neuro-Oncology, Volume 19, Issue suppl_4, 1 June 2017, Pages iv2, doi.org/10.1093/neuonc/nox083.006
 31. Donson, A; Griesinger, A; Amani, V; Witt, D; Apps, J; Grant, G; Dudley, R; Jackson, E; Johnston, J; Greenfield, J; Naftel, R; Limbrick, D; Anderson, RCE; Siani, T; Handler, M; **Mulcahy Levy, J**; Martinez-Barbera, JP; Foreman, N; Hankinson, TC. *Molecular analyses demonstrate an immunosuppressive phenotype in the cyst and solid tumor compartment of adamantinomatous craniopharyngioma*. Neuro-Oncology, Volume 19, Issue suppl_4, 1 June 2017, Pages iv28, doi.org/10.1093/neuonc/nox083.116
 32. Grob, S; Davies, K; Aisner, D; Morin, A; Zahedi, S; Foreman, N; **Mulcahy Levy J**. *The role of BRAF mutations in clinical outcomes in pediatric low-grade spinal cord tumors*. Neuro-Oncology, Volume 19, Issue suppl_4, 1 June 2017, Pages iv36, doi.org/10.1093/neuonc/nox083.147
 33. Zapotocky, M; Ryall, S; Fukuoka, K; Stucklin, AG; Bennett, J; Sumerauer, D; Pavelka, Z; Cruz, O; Solano, P; Garre, ML; Hauser, P; Frappaz, D; Hansford, J; Amayiri, N; Morse, H; Sabel, M; Bechensteen, AG; Su, J; Karajannis, M; Finlay, J; Eisenstat, D; Canete, A; Toledano, H; Dahiya, S; Leary, S; Nicolaidis, T; Finch, E; Mueller, S; **Mulcahy Levy, J**; Ellison, D; Lassaletta, A; Larouche, V; Ramaswamy, V; Dirks, P; McKeown, T; Bartels, U; Bouffet, E; Hawkins, C; Tabori, U; PLGG Taskforce. *Remarkable objective response and favorable survival for BRAF^{V600E} childhood low-grade gliomas to BRAF inhibitors compared to conventional chemotherapy*. Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/noy059.399

34. McEvoy, M; Hemenway, M; Raybin, J; Green, A; Nellan, A; **Mulcahy Levy, J**; Vibhakar, R; Foreman, N; McCourt, E; Dorris, K. *Improvement in visual acuity of pediatric patients with brain tumors with bevacizumab.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.345
35. Amani, V; Donson, A; Griesinger, A; Witt, D; **Mulcahy Levy, J**; Hoffman, L; Hankinson, T; Handler, M; Vibhakar, R; Dorris, K; Foreman, N. *Retinoids as potential chemotherapeutic options for posterior fossa ependymoma of childhood.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.216
36. Amani, V; Donson, A; Griesinger, A; Witt, D; **Mulcahy Levy, J**; Hoffman, L; Hankinson, T; Handler, M; Vibhakar, R; Dorris, K; Foreman, N. *Subgroup-specific therapy options for childhood supratentorial ependymoma.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.215
37. Bhatt, Paraag; Dorris, K; **Mulcahy Levy, J**; Schneider, KW; Suttman, A; Donson, A; Foreman, N; Kleinschmidt-DeMasters, BK; Spence, N; Neuberger, I; Mirsky, D. *Sporadic meningiomas of the pediatric population: A review of neuroradiological, neuropathological and neuro-oncological attributes.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.654
38. Stence, N; **Mulcahy Levy, J**; Hoffman, L; Green, A; Mirsky, D; Neuberger, I; Fenton, L; Maloney, J; Kleinschmidt-DeMasters; Vibhakar, R; Foreman, N; Dorris, K. *Imaging characteristics of BRAF^{V600E} mutated pediatric brain tumors.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, <https://doi.org/10.1093/neuonc/ny059.661>
39. **Mulcahy Levy, J**; Kleinschmidt-Demasters, BK. *H3 K27M-mutated gliomas in adults vs. children share similar histological features and adverse prognosis.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.096
40. Green, A; Flannery, P; Hankinson, T; O'Neill, B; DeSisto, J; Lemma, R; Hoffman, L; Mulcahy Levy, J; Raybin, J; Hemenway, M; Koschmann, C; Handler, M; Foreman, N; Vibhakar, R; Wempe, M; Dorris, K. *Intratumoral pharmacokinetics of chemotherapy in DIPG: Xenograft and initial phase 0 clinical trials results.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.169
41. Lemma, R; DeSisto, J; Flannery, P; Sanford, B; Balakrishnan, I; Madhavan, K; Veo, B; **Mulcahy Levy, J**; Foreman, N; Vibhakar, R; Jones, K; Venkataraman, S; Green, A. *The H3K27M mutation causes wide-ranging changes mediating DIPG tumorigenesis.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.159
42. **Mulcahy Levy, J**; Sanford, B; Morin, A; Green, A; Flannery, P; Jones, K; Banerjee, A; Nazemi, K; Samuel, D; Kilburn, L; Solomon, D; Nicolaides, T. *Analysis of paired BRAF^{V600E} mutant glioma patient samples identifies novel resistance mechanisms to targeted BRAF inhibition.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.709
43. Gilani, A; **Mulcahy Levy, J**; Kleinschmidt-DeMasters, BK. *Non-targeted mutation and fusion analysis can aid in classification and treatment of pediatric gliomas.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.700
44. Zahedi, S; Fitzwalter, BE; Gustafson, DL; Morin, A; Desmarais, M; Hoffman, LM; **Mulcahy Levy, JM**. *Assessment of early stage autophagy inhibition in BRAF^{V600E} brain tumor cell response to chemotherapy.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.378
45. Dorris, K; Channell, J; Hemenway, MS; Baroffio, A; Ellison, M; Brionse, N; Griesinger, A; Donson, A; Madden, JR; Van Essen, C; **Mulcahy Levy, J**; Ambruso, D; Foreman, NK. *Use of Cannabinoids in the Pediatric Central Nervous System Tumor Population.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i168, <https://doi.org/10.1093/neuonc/ny059.633>
46. Morin, A; Soane, C; Pierce, A; Alimova, I; Desmaris, M; Zahedi, S; Vibhakar, R; Griesinger, A; Green, A; Hoffman, L; **Mulcahy Levy, J**. *Validation of proteasome inhibition as a therapeutic target in atypical teratoid/rhabdoid tumors.* Neuro-Oncology, Volume 20, Issue suppl_2, 22 June 2018, Pages i104–i105, doi.org/10.1093/neuonc/ny059.016

1. Gosh, S; Venkataraman, S; Pierce, A; Sola, I; Donson, A; Birks, D; Wang, D; Raabe, EH; Foreman, NK; **Mulcahy Levy JM**; Vibhakar, R. *The chromatin-modifying COMPASS-like complex is a synthetic lethal target in Myc Driven Medulloblastoma.* Mol Cancer, submitted.
2. Green, AL; DeSisto, J; Flannery, P; Lemma, R; Lemieux, M; Ramkissoon, S; Jones, K.; Venkataraman, S; Perry, J; Hui, X; Moroze, E; O'Neill, AF; Dunn, K; DeRyckere, D; Hubbell-Engler, B; Mulcahy Levy, JM; Orkin, S; Graham, DK; Foreman, N; Ligon, Keith; Jones, K; Kung, A; Vibhakar, R. *BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway.* EMBO Mol Med, submitted.